FAST NEWS: CanSino’s Inhaled Covid Booster Gets China Green Light
The latest: CanSino Biologics Inc. (6185.HK; 688185.SH) announced on Sunday that China’s National Medical Products Administration (NMPA) have given emergency use authorization for its inhaled recombinant Covid-19 vaccine for use as…
RELATED ARTICLES
-
Dispute over Covid vaccines casts doubt on Clover Bio recovery
2197.HK
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
ZYBT.US
- BRIEF: Mixue’s Hong Kong IPO gets green light from China’s securities regulator
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
China Oriental Group eyes green escape from overheated steel furnace
0581.HK
Discover hidden China stock gems in our weekly newsletter